Pangaea Oncology Statistics

Total Valuation

Pangaea Oncology has a market cap or net worth of EUR 61.50 million. The enterprise value is 64.18 million.

Market Cap	61.50M
Enterprise Value	64.18M

Important Dates

The last earnings date was Tuesday, October 29, 2024.

Earnings Date	Oct 29, 2024
Ex-Dividend Date	n/a

Share Statistics

Pangaea Oncology has 34.36 million shares outstanding. The number of shares has increased by 3.35% in one year.

Current Share Class	n/a
Shares Outstanding	34.36M
Shares Change (YoY)	+3.35%
Shares Change (QoQ)	-1.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.48%
Float	12.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.79
PB Ratio	3.35
P/TBV Ratio	6.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-12.03
EV / Sales	4.47
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-22.14

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.23.

Current Ratio	1.15
Quick Ratio	1.04
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	-1.34
Interest Coverage	-13.79

Financial Efficiency

Return on equity (ROE) is -29.97% and return on invested capital (ROIC) is -11.48%.

Return on Equity (ROE)	-29.97%
Return on Assets (ROA)	-9.44%
Return on Capital (ROIC)	-11.48%
Revenue Per Employee	90,280
Profits Per Employee	-33,563
Employee Count	149
Asset Turnover	0.55
Inventory Turnover	3.84

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +21.77% in the last 52 weeks. The beta is 0.07, so Pangaea Oncology's price volatility has been lower than the market average.

Beta (5Y)	0.07
52-Week Price Change	+21.77%
50-Day Moving Average	1.70
200-Day Moving Average	1.53
Relative Strength Index (RSI)	69.59
Average Volume (20 Days)	543

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pangaea Oncology had revenue of EUR 14.35 million and -5.34 million in losses. Loss per share was -0.18.

Revenue	14.35M
Gross Profit	11.77M
Operating Income	-3.95M
Pretax Income	-4.27M
Net Income	-5.34M
EBITDA	-3.26M
EBIT	-3.95M
Loss Per Share	-0.18

Full Income Statement

Balance Sheet

The company has 1.86 million in cash and 3.90 million in debt, giving a net cash position of -2.04 million or -0.06 per share.

Cash & Cash Equivalents	1.86M
Total Debt	3.90M
Net Cash	-2.04M
Net Cash Per Share	-0.06
Equity (Book Value)	16.92M
Book Value Per Share	0.53
Working Capital	1.12M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.65 million and capital expenditures -244,444, giving a free cash flow of -2.90 million.

Operating Cash Flow	-2.65M
Capital Expenditures	-244,444
Free Cash Flow	-2.90M
FCF Per Share	-0.08

Full Cash Flow Statement

Margins

Gross margin is 82.01%, with operating and profit margins of -27.52% and -37.18%.

Gross Margin	82.01%
Operating Margin	-27.52%
Pretax Margin	-29.74%
Profit Margin	-37.18%
EBITDA Margin	-22.70%
EBIT Margin	-27.52%
FCF Margin	-20.19%

Dividends & Yields

Pangaea Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.35%
Shareholder Yield	-3.35%
Earnings Yield	-9.80%
FCF Yield	-4.71%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Pangaea Oncology has an Altman Z-Score of 2.91. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.91
Piotroski F-Score	n/a